Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28265604 | 0.75 | HDAC6 (0.32) | MAP2K2MAP2K1 | |
| SCHEMBL7529082 | 0.68 | MAOB (0.40) | TDP1MAOB | |
| SCHEMBL15550000 | 0.67 | BAZ2B (0.45) | BAZ2BBAZ2AMAP2K2MAP2K1ATAD2 | |
| SCHEMBL28223520 | 0.66 | HRAS (0.36) | POLB | |
| SCHEMBL27467128 | 0.64 | ADORA2A (0.37) | POLB | |
| SCHEMBL28026875 | 0.64 | ALDH1A1 (0.40) | POLB | |
| SCHEMBL2088762 | 0.64 | RAB9A (0.46) | GAAPOLB | |
| SCHEMBL31133035 | 0.63 | BAZ2B (0.69) | BAZ2BBAZ2AMAP2K2MAP2K1GAA | |
| SCHEMBL31574401 | 0.63 | BAZ2B (0.45) | BAZ2BBAZ2AMAP2K2MAP2K1TDP1 | |
| SCHEMBL30132193 | 0.63 | CA1 (0.50) | POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |